ANNUAL GENERAL MEETING OF SHAREHOLDERS OF

AKARI THERAPEUTICS, PLC

June 30, 2026

2:30 pm GMT (9:30 am Eastern Time)

This proxy is being solicited on behalf of the Board of Directors

ADD YOUR EMAIL ADDRESS ONLINE

Add your email address to your online account at Equiniti for 24/7 access to your account and enroll in eConsent to receive future materials electronically. Update your account today at: equiniti.com/us/ast-access (see reverse side for instructions) or provide us with your email address in the section entitled **Electronic Shareholder Communications** at the bottom right side of this card to receive future materials electronically when available.

Please vote, sign, date and mail your proxy card in the envelope provided so that your vote is received on or before June 18, 2026, at 1:00 pm Eastern Time.

Please detach along perforated line and mail in the envelope provided.

THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS THAT YOU VOTE "FOR" EACH OF THE RESOLUTIONS TO BE CONSIDERED AT THE GENERAL MEETING. PLEASE VOTE ONLINE OR BY TELEPHONE USING BLUE OR BLACK INK AS SHOWN HERE ☒ AND RETURN IN THE ENVELOPE. VOTES MUST BE RECEIVED BY 1:00 PM EASTERN TIME ON June 18, 2026

Ordinary Resolutions

	FOR	AGAINST	ABSTAIN
1. To receive the report of the Board of Directors and the accounts for the year ended December 31, 2025, together with the report of the statutory auditor and the strategic report.	☐	☐	☐
2. To approve, on an advisory-basis, the Board of Directors' Remuneration Report (excluding the Board of Directors' Remuneration Policy), as set out in the Company's annual report and accounts for the financial year ended December 31, 2025.	☐	☐	☐
3. To approve the Directors' Remuneration Policy, as set out on pages 13 to 16 of the Directors' Remuneration Report.	☐	☐	☐
4. To re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Company's articles of association (the "**Articles**").	☐	☐	☐
5. To re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
6. To re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
7. To re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
8. To re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
9. To re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
10. To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2026.	☐	☐	☐
11. To re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.	☐	☐	☐
12. To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors' remuneration.	☐	☐	☐
13. To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.	☐	☐	☐
14. To authorize, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, pursuant to the Company's ELOC Purchase Agreement (as defined herein).	☐	☐	☐
15. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of (i) Series H Warrants, Series I Warrants and Series J Warrants to purchase up to an aggregate of 4,411,764 American Depositary Shares ("ADSs") pursuant to a securities purchase agreement dated May 20, 2026 and the issuance of the ADSs and ordinary shares underlying such warrants, and (ii) an aggregate of 117,647 placement agent ADSs pursuant to a placement agent agreement dated May 20, 2026.	☐	☐	☐
16. To approve, for the purposes of complying with Nasdaq Listing Rule 5635(b), the potential issuance of shares in a private placement offering, which would result in a "change of control" of the Company.	☐	☐	☐
17. To generally and unconditionally authorize to allot shares.	☐	☐	☐

Special Resolution

	FOR	AGAINST	ABSTAIN
18. To approve the Pre-emption Rights Proposal.	☐	☐	☐

To change the address on your account or to add the email, please check the box at right. ☐

Please indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

Electronic Shareholder Communications Please join the growing number of shareholders who receive emails instead of hard copy shareholder communications. Register online at equiniti.com/us/ast-access or supply your email address here.

Signature of Shareholder ______ Date: ______ Signature of Shareholder ______ Date: ______

Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.

0

AKARI THERAPEUTICS, PLC

Proxy for the Annual General Meeting of Shareholders on June 30, 2026 2:30 pm GMT (9:30 am Eastern Time)

ADD YOUR EMAIL ADDRESS ONLINE

Add your email address to your online account to enroll in eConsent and receive future materials electronically.

For **first time users** setting up an account:

- Visit equiniti.com/us/ast-access.
- Under **Individuals** click on LOGIN. A new screen will appear.
- Under **Shareholder Central** click **First Time Registration**.
- Follow the instructions provided to set up your account which will include providing your e-mail address.
- Once your account has been set up click on your username at the top right of the screen. From the drop down select **My profile** which opens another window.
- In the box labeled Document Delivery select the option **Enroll in e-Delivery of Documents**.
- Finally, click the Submit button. Any future proxy materials will be sent to the primary email address on the account, should they be available.

For **existing users** updating your account:

- Visit equiniti.com/us/ast-access.
- Under **Individuals** click on LOGIN. A new screen will appear.
- Under **Shareholder Central** click LOGIN. Enter your username and password.
- Click on your username at the top right of the screen. From the drop down select **My profile** which opens another window.
- In the box labeled Document Delivery select the option **Enroll in e-Delivery of Documents**.
- Finally, click the Submit button. Any future proxy materials will be sent to the primary email address on the account, should they be available.

Alternatively, you can provide your email address in the section on the reverse entitled **Electronic Shareholder Communications**.

GENERAL MEETING OF SHAREHOLDERS OF

AKARI THERAPEUTICS, PLC

June 30 2026, at 2:30 pm GMT (9:30 am Eastern Time)

PROXY VOTING INSTRUCTIONS

INTERNET - Access **www.voteproxy.com** and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy card available when you access the web page.

TELEPHONE - Call toll-free **1-800-PROXIES** (1-800-776-9437) in the United States or **+1-201-299-4446** worldwide from any touch-tone telephone and follow the instructions. Have your proxy card available when you call.

Vote online or by phone until 1:00 pm Eastern Time on June 18, 2026.

ADD YOUR EMAIL ADDRESS ONLINE - Add your email address to your online account and enroll in eConsent to receive future materials electronically. Update your account at: equiniti.com/us/ast-access (see reverse side for instructions) or provide us with your email address in the section **Electronic Shareholder Communications** at the bottom right side of this card to receive future materials electronically when available.

COMPANY NUMBER	
ACCOUNT NUMBER	

Please detach along perforated line and mail in the envelope provided.

THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS THAT YOU VOTE "FOR" EACH OF THE RESOLUTIONS TO BE CONSIDERED AT THE GENERAL MEETING. PLEASE VOTE ONLINE OR BY TELEPHONE USING BLUE OR BLACK INK AS SHOWN HERE ☒ AND RETURN IN THE ENVELOPE. VOTES MUST BE RECEIVED BY 1:00 PM EASTERN TIME ON June 18, 2026

Ordinary Resolutions

	Resolution	FOR	AGAINST	ABSTAIN
1.	To receive the report of the Board of Directors and the accounts for the year ended December 31, 2025, together with the report of the statutory auditor and the strategic report.	☐	☐	☐
2.	To approve, on an advisory-basis, the Board of Directors' Remuneration Report (excluding the Board of Directors' Remuneration Policy), as set out in the Company's annual report and accounts for the financial year ended December 31, 2025.	☐	☐	☐
3.	To approve the Directors' Remuneration Policy, as set out on pages 13 to 16 of the Directors' Remuneration Report.	☐	☐	☐
4.	To re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Company's articles of association (the "**Articles**").	☐	☐	☐
5.	To re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
6.	To re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
7.	To re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
8.	To re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
9.	To re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.	☐	☐	☐
10.	To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2026.	☐	☐	☐
11.	To re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.	☐	☐	☐
12.	To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors' remuneration.	☐	☐	☐
13.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.	☐	☐	☐
14.	To authorize, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, pursuant to the Company's ELOC Purchase Agreement (as defined herein).	☐	☐	☐
15.	To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of (i) Series H Warrants, Series I Warrants and Series J Warrants to purchase up to an aggregate of 4,411,764 American Depositary Shares ("ADSs") pursuant to a securities purchase agreement dated May 20, 2026 and the issuance of the ADSs and ordinary shares underlying such warrants, and (ii) an aggregate of 117,647 placement agent ADSs pursuant to a placement agent agreement dated May 20, 2026.	☐	☐	☐
16.	To approve, for the purposes of complying with Nasdaq Listing Rule 5635(b), the potential issuance of shares in a private placement offering, which would result in a "change of control" of the Company.	☐	☐	☐
17.	To generally and unconditionally authorize to allot shares.	☐	☐	☐

Special Resolution

	Resolution	FOR	AGAINST	ABSTAIN
18.	To approve the Pre-emption Rights Proposal.	☐	☐	☐

To change the address on your account or to add the email, please check the box at right. ☐

Please indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

Electronic Shareholder Communications Please join the growing number of shareholders who receive emails instead of hard copy shareholder communications. Register online at equiniti.com/us/ast-access or supply your email address here.

Signature of Shareholder ____________ Date: ________ Signature of Shareholder ____________ Date: ________

Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.